Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
RECORDATI SHAREHOLDERS APPROVE THE 2014 ACCOUNTS. DIVIDEND € 0.50 PER SHARE (+51.5% vs 2013). Shareholders approve the 2014 results: consolidated revenues € 987.4 million...
RECORDATI; BOARD APPROVES THE 2014 ACCOUNTS. REVENUES € 987.4 MILLION (+4.9%), OPERATING INCOME € 231.0 MILLION (+18.2%), NET INCOME € 161.2 MILLION (+20.6%). 2014 DIVIDEND...
PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT, SALES +4.9%, OPERATING INCOME +18.2% AND NET INCOME +20.6%. Consolidated revenue € 987.3 million...
RECORDATI REPORTS EXCELLENT RESULTS IN THE FIRST HALF 2014. SALES +6.3%, OPERATING INCOME +18.8% AND NET INCOME +18.1%. Consolidated revenue € 507.6 million, + 6.3%. EBITDA(1...
MILANO, Italy, July 3, 2014 (GLOBE NEWSWIRE) -- Recordati announces that the U.S. Food and Drug Administration (FDA) has granted approval of Orphan Europe's request for orphan drug designation...
MILANO, Italy, May 26, 2014 (GLOBE NEWSWIRE) -- Recordati announces, following its previous releases dated 24 July 2013 and 31 October 2013, the successful conclusion of the acquisition of a...
Consolidated revenue € 260.4 million, +6.5%. EBITDA(1) € 71.4 million, +16.4% Operating income € 62.2 million, +18.1%. Net income € 42.8 million...
Shareholders approve the 2013 results: Consolidated revenue € 941.6 million, +13.7%, operating income € 195.4 million, +17.0%, net income € 133.7 million...
MILANO, Italy, March 6, 2014 (GLOBE NEWSWIRE) -- RECORDATI: BOARD APPROVES THE 2013 ACCOUNTS. REVENUE € 941.6 MILLION (+13.7%), OPERATING INCOME € 195.4 MILLION (+17.0%), NET...
LA DEFENSE, France, Feb. 26, 2014 (GLOBE NEWSWIRE) -- EURORDIS (European Organisation for Rare Diseases) announced yesterday that Orphan Europe has been awarded the prestigious EURORDIS Company...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FU |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
